Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Stimulating Invariant Natural Killer T-Cells to Boost Immune System in Fight Against Cancer with Dr. Ian Walters Portage Biotech TRANSCRIPT
Download PDFMay 25, 2021
Dr. Ian Walters is CEO of Portage Biotech is building a pipeline of novel immunotherapies for the treatment of cancer particularly for patients who do not respond to current therapies. The key is stimulating a type of immune cell called invariant natural killer T-cell which works with the adaptive immune system to create a broad immune response and stronger immune surveillance to help stop cancer from forming in the body.
Having contributed to bringing five new blockbuster cancer drugs to patients, Ian and his team are working to hit all key components for every different tumor type for a long-term response and possible cure. They think their drug could have potential in settings that wouldn't respond to just pure NK cell therapy.
#ImmunoOncology #Cancer #iNKT #biotech $PRTG
